Rezolute(US:RZLT) Newsfile·2025-12-13 12:38Group 1 - Rezolute, Inc. shares experienced a significant decline of approximately 85-90% following disappointing results from its Phase 3 sunRIZE clinical trial for the drug candidate ersodetug, which failed to meet primary and key secondary endpoints [4][5] - The highest dose in the trial showed reductions in hypoglycemia events that were not statistically significant compared to placebo, leading to investor concerns [4] - Trading of Rezolute's stock was halted under Nasdaq's volatility controls due to the drastic drop in share price, which fell from around $10.94 to an intraday low near $0.90 [5] Group 2 - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. for investors who suffered significant losses [2] - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3] - Investors are encouraged to contact the firm to discuss their legal rights and options following the stock's decline [1]